Lifecore Biomedical, Inc. LFCR 深 滬
已收盤 05-08 16:00:00 美东时间
4.79
+0.020
+0.42%
華盛通- 最 高4.85
- 今 開4.73
- 成交量 20.52万股
- 最 低 4.67
- 昨 收 4.77
- 總市值 1.80亿
- 52周最高 8.9799
- 市盈率 靜 --
- 換手率 0.55%
- 52周最低 3.625
- 委 比 20.06%
- 總股本 3747.74万
- 歷史最高 15.96
- 量 比 1.15
- 振 幅 3.77%
- 歷史最低 1.52
- 每 手 1
- 風險率 1.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Lifecore Biomedical Q1 2026 Earnings Call Transcript
Lifecore Biomedical (NASDAQ:LFCR) held its first-quarter earnings conference ca...
05-06 20:58
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.430 million estimate.
05-06 19:21
Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.24) by 79.17 percent. This is a 18.87 percent increase over losses of $(0.53) per share
05-06 19:20
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.
04-30 04:59
Lifecore Biomedical Earnings Call Signals Profitable Shift
Lifecore Biomedical, Inc. (($LFCR)) has held its Q5 earnings call. Read on for ...
03-29 08:12
